Novartis hopes for better luck with bispecifics via $150M upfront Dren Bio deal

Novartis has had some bad luck with bispecific antibodies in the past, but judging by the pharma's latest deal it still has faith in the modality.

Under the terms of this partnership, Bay Area-based Dren Bio and Novartis will collaborate on discovering and developing new bispecific antibodies for cancer using Dren Bio’s Targeted Myeloid Engager and Phagocytosis Platform, according to a Wednesday release.